Verona Total Stockholder Equity from 2010 to 2024
| VRNA Stock | USD 39.90 0.06 0.15% |
Total Stockholder Equity | First Reported 2005-06-30 | Previous Quarter 168.3 M | Current Value 130.5 M | Quarterly Volatility 87.1 M |
Check Verona Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Verona Pharma's main balance sheet or income statement drivers, such as Interest Expense of 2.2 M, Selling General Administrative of 45.9 M or Other Operating Expenses of 71.2 M, as well as many indicators such as Price To Sales Ratio of 4.1 K, Dividend Yield of 0.0 or PTB Ratio of 6.01. Verona financial statements analysis is a perfect complement when working with Verona Pharma Valuation or Volatility modules.
Verona | Total Stockholder Equity |
Latest Verona Pharma's Total Stockholder Equity Growth Pattern
Below is the plot of the Total Stockholder Equity of Verona Pharma PLC over the last few years. It is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. Verona Pharma's Total Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Verona Pharma's overall financial position and show how it may be relating to other accounts over time.
| Total Stockholder Equity | 10 Years Trend |
|
Total Stockholder Equity |
| Timeline |
Verona Total Stockholder Equity Regression Statistics
| Arithmetic Mean | 92,838,713 | |
| Geometric Mean | 35,309,124 | |
| Coefficient Of Variation | 104.94 | |
| Mean Deviation | 83,369,940 | |
| Median | 44,402,632 | |
| Standard Deviation | 97,429,564 | |
| Sample Variance | 9492.5T | |
| Range | 260.1M | |
| R-Value | 0.92 | |
| Mean Square Error | 1627.7T | |
| R-Squared | 0.84 | |
| Slope | 19,976,288 | |
| Total Sum of Squares | 132895.3T |
Verona Total Stockholder Equity History
About Verona Pharma Financial Statements
Verona Pharma stakeholders use historical fundamental indicators, such as Verona Pharma's Total Stockholder Equity, to determine how well the company is positioned to perform in the future. Although Verona Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Verona Pharma's assets and liabilities are reflected in the revenues and expenses on Verona Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Verona Pharma PLC. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Stockholder Equity | 249.3 M | 261.7 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Verona Pharma PLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Verona Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Verona Pharma Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Verona Pharma Plc Stock:Check out the analysis of Verona Pharma Correlation against competitors. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verona Pharma. If investors know Verona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verona Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.00) | Revenue Per Share 0.07 | Return On Assets (0.28) | Return On Equity (0.78) |
The market value of Verona Pharma PLC is measured differently than its book value, which is the value of Verona that is recorded on the company's balance sheet. Investors also form their own opinion of Verona Pharma's value that differs from its market value or its book value, called intrinsic value, which is Verona Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verona Pharma's market value can be influenced by many factors that don't directly affect Verona Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verona Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verona Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verona Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.